ST Bailing announced that 12 of its major products, including Yindan Xinnaotong Soft Capsules, Xiaoer Chaigui Tuire Granules, and Hugan Tablets, have been selected for the National Essential Medicines List, 2026 Edition. Among them, Yindan Xinnaotong Soft Capsules is the company's core exclusive product, has been approved as the first traditional Chinese medicine secondary protected variety, and is a core representative of Miao medicine going global. The new list was jointly issued by the National Health Commission and two other departments, containing a total of 794 medicines, and will take effect from September 1, 2026. This marks the first update in eight years since the 2018 edition. ST Bailing stated that this selection represents high-level national recognition of the products' clinical value and public benefit attributes, which will facilitate their promotion and use in medical institutions at all levels, and will have a positive impact on the company's market expansion and long-term development.
Guizhou Bailing Group Pharmaceutical Co Ltd12 major products selected for 2026 National Essential Medicines List, facilitating promotion and use in medical institutions.